Neuroscience News and Research

RSS

Diet rich in omega-3 fatty acids linked to improved nervous-system function

The omega-3 essential fatty acids commonly found in fatty fish and algae help animals avoid sensory overload, according to research published by the American Psychological Association.

17 Dec 2009

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.

16 Dec 2009

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) today voted 12 yes, 4 no, and 1 abstention that AstraZeneca has established sufficient benefit to offset the observed risks to support the use of CRESTOR®

16 Dec 2009

U.S. patent for new bioadhesive drug delivery system awarded to SRI International

SRI International, an independent nonprofit research and development organization, announced today the award of U.S. patent 7,592,021 for a new bioadhesive drug delivery system that enables enhanced release of drugs through the human body's mucous membranes.

16 Dec 2009

Lilly Endowment offers $60 million to implement the Indiana Physician Scientist Initiative

When a patient has a disease that can't be treated effectively, the physician can see clearly where research is needed.

15 Dec 2009

Patheon releases the first commercial shipments of SUMAVEL DosePro to Zogenix

Patheon a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that it has successfully released the first commercial shipments of SUMAVEL DosePro (sumatriptan injection) to Zogenix in anticipation of the planned U.S. commercial product launch scheduled in January 2010.

15 Dec 2009

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

AstraZeneca and the University of Virginia (UVa) in Charlottesville, today announced that they have entered into a strategic research collaboration to enhance development of new treatments primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).

15 Dec 2009

RORalpha protein revealed as an essential regulator of inflammatory factors

How do the brain cells called astrocytes ensure the protection of neurons? By studying the protagonists in the protection and satisfactory functioning of neurons, scientists at the Laboratoire Neurobiologie des Processus Adaptatifs (CNRS/UPMC) have found a mechanism that clarifies the role of astrocytes.

15 Dec 2009

Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified

Elan Corporation, plc and Transition Therapeutics, Inc. today notified clinical investigators of modifications to the Phase II study AD201 and open label extension study AD251 for ELND005, a compound being developed for the potential treatment of Alzheimer’s disease.

15 Dec 2009

Nanoparticle could allow diagnosis and treatment in one visit

Researchers at Rice University and Baylor College of Medicine (BCM) have created a single nanoparticle that can be tracked in real time with MRI as it homes in on cancer cells, tags them with a fluorescent dye and kills them with heat.

15 Dec 2009

USPTO issues Notice of Allowance to Transcept Pharmaceuticals for Intermezzo claims

Transcept Pharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/060,641, which covers the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate.

15 Dec 2009

Teva Pharmaceutical Industries receives approval for newly revised prescribing information for AZILECT

Teva Pharmaceutical Industries, Ltd. today announced the U.S. Food and Drug Administration (FDA) approved the newly revised prescribing information for AZILECT® (rasagiline tablets) reducing medication and food restrictions.

15 Dec 2009

Postmenopausal women who take antidepressants face increased risk for stroke and death

Postmenopausal women who take antidepressants face a small but statistically significant increased risk for stroke and death compared with those who do not take the drugs. The new findings are from the federally-funded, multi-institution, Women's Health Initiative Study sponsored by the National Institutes of Health, and the results are published in the December 14 online edition of Archives of Internal Medicine.

14 Dec 2009

Psychopharmacology expert calls for more mental health staffing at army bases

The recent shootings at the Ft. Hood, Texas army base, allegedly by an army psychiatrist, have placed much-needed focus on mental health care in the army. In an article published in the December issue of the journal CNS Spectrum, renowned psychopharmacology expert Stephen M. Stahl, MD, PhD, calls for increased mental health staffing at Fort Hood and other army bases.

14 Dec 2009

New biosensors show how schizophrenia drugs alter brain chemistry

Scientists have resolved a question about how a popular class of drugs used to treat schizophrenia works using biosensors that reveal previously hidden components of chemical communication in the brain.

14 Dec 2009

Oconomowoc Memorial Hospital performs partial knee resurfacing surgery using MAKOplasty technology

For the first time in Wisconsin, patients suffering from arthritis pain have access to a new procedure that uses the precision of robotics to perform partial knee resurfacing surgery. The technology, called MAKOplasty®, is a minimally invasive surgical option that results in shorter hospital stays and faster healing than traditional knee surgeries.

11 Dec 2009

Scientists explore new potential therapies for Parkinson's disease

Following up on their previous work showing the rescue of dopamine neurons by chemicals that interact with the retinoid X receptor (RXR), researchers have now investigated the potential of these chemicals, known as RXR ligands, for the treatment of Parkinson's disease.

11 Dec 2009

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%

11 Dec 2009

Mouse study shows delaying the ageing process may offer protection against Alzheimer’s disease

Aging is the single greatest risk factor for Alzheimer's disease. In their latest study, researchers at the Salk Institute for Biological Studies found that simply slowing the aging process in mice prone to develop Alzheimer's disease prevented their brains from turning into a neuronal wasteland.

10 Dec 2009

New brain metastases treatment guidelines

New treatment guidelines for patients with brain metastases are now available from the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS).

10 Dec 2009

Neuroscience News and Research

Diet rich in omega-3 fatty acids linked to improved nervous-system function

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

U.S. patent for new bioadhesive drug delivery system awarded to SRI International

Lilly Endowment offers $60 million to implement the Indiana Physician Scientist Initiative

Patheon releases the first commercial shipments of SUMAVEL DosePro to Zogenix

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

RORalpha protein revealed as an essential regulator of inflammatory factors

Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified

Nanoparticle could allow diagnosis and treatment in one visit

USPTO issues Notice of Allowance to Transcept Pharmaceuticals for Intermezzo claims

Teva Pharmaceutical Industries receives approval for newly revised prescribing information for AZILECT

Postmenopausal women who take antidepressants face increased risk for stroke and death

Psychopharmacology expert calls for more mental health staffing at army bases

New biosensors show how schizophrenia drugs alter brain chemistry

Oconomowoc Memorial Hospital performs partial knee resurfacing surgery using MAKOplasty technology

Scientists explore new potential therapies for Parkinson's disease

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

Mouse study shows delaying the ageing process may offer protection against Alzheimer’s disease

New brain metastases treatment guidelines

Neuroscience - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News